RhumbLine Advisers’s Actinium Pharmaceuticals ATNM Stock Holding History

RhumbLine Advisers’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-42,284	Closed	-$68.1K	–	4148
2025 Q1	$68.1K	Buy	42,284 +1,564	+4%	+$1.99K	﹤0.01%	3495
2024 Q4	$51.3K	Buy	40,720 +1,724	+4%	+$2.67K	﹤0.01%	3647
2024 Q3	$73.3K	Sell	38,996 -660	-2%	-$2.61K	﹤0.01%	3597
2024 Q2	$293K	Buy	39,656 +7,525	+23%	+$62K	﹤0.01%	3015
2024 Q1	$252K	Buy	32,131 +483	+2%	+$3.1K	﹤0.01%	3068
2023 Q4	$161K	Buy	31,648 +882	+3%	+$4.54K	﹤0.01%	3285
2023 Q3	$182K	Buy	30,766 +1,116	+4%	+$7.43K	﹤0.01%	3209
2023 Q2	$220K	Buy	+29,650	New	+$252K	﹤0.01%	3192
2015 Q2	–	Sell	-469	Closed	-$35K	–	3035
2015 Q1	$35K	Buy	+469	New	+$55.8K	﹤0.01%	3011

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

RhumbLine Advisers's ATNM Position: Q2 2025 in Review

RhumbLine Advisers sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 42,284 shares — an estimated $68.1K sold.

RhumbLine Advisers first reported a position in ATNM in Q1 2015 and held it in 9 quarters. The position peaked at $293K in Q2 2024. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

RhumbLine Advisers reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
RhumbLine Advisers sold 42,284 Actinium Pharmaceuticals shares in Q2 2025, an estimated $68.1K.
RhumbLine Advisers first reported a position in Actinium Pharmaceuticals in Q1 2015 and held it in 9 quarters.
RhumbLine Advisers's Actinium Pharmaceuticals position peaked at $293K in Q2 2024.
63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.